We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+12.99%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$1.12B
AUM Growth
+$199M
Cap. Flow
+$144M
Cap. Flow %
12.84%
Top 10 Hldgs %
31%
Holding
95
New
1
Increased
36
Reduced
12
Closed
13

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$56.1M
2
LLY icon
Eli Lilly
LLY
+$9.29M
3
MDT icon
Medtronic
MDT
+$9.04M
4
CI icon
Cigna
CI
+$7.04M
5
ELV icon
Elevance Health
ELV
+$6.73M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$12.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.59M
3
BMY icon
Bristol-Myers Squibb
BMY
+$5.42M
4
AIMT
Aimmune Therapeutics
AIMT
+$4.76M
5
OMCL icon
Omnicell
OMCL
+$4.24M

Sector Composition

Rank Sector Weight
1 Healthcare 94.2%
2 Communication Services 2.08%
3 Industrials 0.52%
4 Technology 0.02%
5 Energy 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAS
51
DELISTED
Exact Sciences
EXAS
$8.16M 0.73%
80,000
– –
BDX icon
52
Becton Dickinson
BDX
$48.8B
$8.14M 0.72%
35,875
+14,350
+67% +$3.53M
NBIX icon
53
Neurocrine Biosciences
NBIX
$16.5B
$7.21M 0.64%
75,000
– –
GKOS icon
54
Glaukos
GKOS
$10.8B
$6.93M 0.62%
140,000
– –
APLS
55
DELISTED
Apellis Pharmaceuticals
APLS
$6.79M 0.6%
225,000
+60,000
+36% +$1.79M
ADVM
56
DELISTED
Adverum Biotechnologies
ADVM
$6.44M 0.57%
62,500
+12,500
+25% +$1.87M
SGMO
57
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$6.38M 0.57%
675,000
– –
KYNB
58
Kyntra Bio
KYNB
$28.9M
$5.96M 0.53%
5,800
– –
ACCD
59
DELISTED
Accolade Inc
ACCD
$5.9M 0.52%
+151,674
New +$5.23M
BLUE
60
DELISTED
bluebird bio
BLUE
$5.82M 0.52%
8,322
– –
RVNC
61
DELISTED
Revance Therapeutics, Inc.
RVNC
$5.53M 0.49%
220,000
– –
MYOV
62
DELISTED
Myovant Sciences Ltd.
MYOV
$5.34M 0.47%
380,000
+230,000
+153% +$4.28M
ALKS icon
63
Alkermes
ALKS
$8.25B
$5.14M 0.46%
310,000
– –
RARE icon
64
Ultragenyx Pharmaceutical
RARE
$2.66B
$5.05M 0.45%
61,500
– –
MGTX icon
65
MeiraGTx Holdings
MGTX
$1.2B
$4.96M 0.44%
375,000
+75,000
+25% +$987K
SWAV
66
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$4.55M 0.4%
60,000
– –
RIGL icon
67
Rigel Pharmaceuticals
RIGL
$781M
$4.17M 0.37%
173,618
– –
DVAX
68
DELISTED
Dynavax Technologies
DVAX
$4M 0.36%
925,534
– –
RDUS
69
DELISTED
Radius Health, Inc.
RDUS
$3.76M 0.33%
331,826
– –
INCY icon
70
Incyte
INCY
$24.4B
$3.59M 0.32%
40,000
– –
EPZM
71
DELISTED
Epizyme, Inc
EPZM
$3.16M 0.28%
265,000
– –
AGIO icon
72
Agios Pharmaceuticals
AGIO
$1.98B
$3.15M 0.28%
90,000
– –
VRAY
73
DELISTED
ViewRay, Inc.
VRAY
$2.71M 0.24%
775,000
– –
CLLS
74
Cellectis
CLLS
$283M
$2.67M 0.24%
144,604
– –
GTHX
75
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.19M 0.2%
190,000
– –
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2020 Portfolio in Review

As of Q3 2020, Rhenman & Partners Asset Management held 95 positions worth $1.12B, up 22% from $926M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $144M of net new capital in Q3 2020, opening 1 new position and adding to 36 existing holdings. Its largest new stake was Accolade Inc: 151,674 shares worth $5.9M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Communication Services and Industrials.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $12.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2020 buy was Accolade Inc: 151,674 shares worth $5.9M.
  • Rhenman & Partners Asset Management added most to BioMarin Pharmaceuticals in Q3 2020, an estimated $56.1M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2020 reduction was Immunomedics Inc, cutting an estimated $12.1M.
  • Rhenman & Partners Asset Management fully exited Aimmune Therapeutics in Q3 2020, selling an estimated $4.76M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $1.12B portfolio in Q3 2020.
  • Rhenman & Partners Asset Management opened 1 new position and closed 13 in Q3 2020.
  • Rhenman & Partners Asset Management's portfolio value rose 22% quarter-over-quarter to $1.12B.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2020, filed 13 Oct 2020.